The Basal Cell Carcinoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Basal Cell Carcinoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Basal Cell Carcinoma pipeline landscape and fostering the potential growth of Basal Cell Carcinoma therapeutic advancements.

 

Key Takeaways from the Basal Cell Carcinoma Pipeline Report

• DelveInsight’s Basal Cell Carcinoma pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Basal Cell Carcinoma treatment.
• The leading companies working in the Basal Cell Carcinoma market include PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others.
• Promising Basal Cell Carcinoma Pipeline Therapies in the various stages of development include BF-200 ALA, Methyl-aminolevulinate, Cemiplimab, STP705, Patidegib, LDE225, Imiquimod, Vismodegib, and others.
• On March 2023, Sirnaomics announced a study of Phase 2 Clinical Trials for This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with Basal Cell Carcinoma (BCC).
• On June 2023, Regeneron Pharmaceuticals announced a study of Phase 1 Clinical Trials for Cemiplimab. The primary objective is to characterize the safety and tolerability of cemiplimab injected intralesionally in patients with Cutaneous Squamous Cell Carcinoma (CSCC) or Basal Cell Carcinoma (BCC).

 

Request a sample and discover the recent advances in Basal Cell Carcinoma Treatment Drugs @ Basal Cell Carcinoma Pipeline Report

 

The Basal Cell Carcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Basal Cell Carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Basal Cell Carcinoma clinical trial landscape.

 

Basal Cell Carcinoma Overview

Basal Cell Carcinoma (BCC) is a common, locally invasive, keratinocyte cancer (also known as nonmelanoma cancer). It is the most common form of skin cancer. BCC is also known as rodent ulcer and basalioma.

 

Find out more about Basal Cell Carcinoma Treatment Drugs @ Drugs for Basal Cell Carcinoma Treatment

 

Basal Cell Carcinoma Emerging Drugs Profile

• Patidegib: PellePharm
• AIV001: AiViva BioPharma

 

Basal Cell Carcinoma Pipeline Therapeutics Assessment

The Basal Cell Carcinoma pipeline report proffers an integral view of the Basal Cell Carcinoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Learn more about the emerging Basal Cell Carcinoma Pipeline Therapies @ Basal Cell Carcinoma Clinical Trials Assessment

 

Scope of the Basal Cell Carcinoma Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Basal Cell Carcinoma Companies- PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others.
• Basal Cell Carcinoma Pipeline Therapies- BF-200 ALA, Methyl-aminolevulinate, Cemiplimab, STP705, Patidegib, LDE225, Imiquimod, Vismodegib, and others.

 

Dive deep into rich insights for new drugs for Basal Cell Carcinoma Treatment, Visit @ Basal Cell Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Basal Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Basal Cell Carcinoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Patidegib: PellePharm
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. IO103: IO Biotech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. AIV001: AiViva BioPharma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Cannabidiol: Leaf Vertical
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Basal Cell Carcinoma Key Companies
21. Basal Cell Carcinoma Key Products
22. Basal Cell Carcinoma- Unmet Needs
23. Basal Cell Carcinoma- Market Drivers and Barriers
24. Basal Cell Carcinoma- Future Perspectives and Conclusion
25. Basal Cell Carcinoma Analyst Views
26. Appendix

 

For further information on the Basal Cell Carcinoma Pipeline therapeutics, reach out to Basal Cell Carcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting